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The Japanese Pediatric Asthma Guideline was revised in November of 2002. The guideline, the JPGL2002,
has several characteristics different from other asthma guidelines. One of the important differences is the clas-
sification of asthma severity ; the frequencies of asthma symptoms in Steps 2, 3 and 4 of the JPGL2002 are
similar to those of Steps 1, 2 and 3, respectively, of the Global Initiative for Asthma (GINA). In the JPGL2002,
infantile asthma is classified separately, considering the necessity of special concern due to the characteristic
features, and three different protocols for long-term management are provided according to the patients’ ages :
younger than 2 years, 2 to 5 years, and older than 5 years. For patients older than 5 years, inhaled glucocorti-
costeroid (ICS) is recommended for asthma with symptoms more than once a month but less than once a week
(Step 2). The GINA classifies this as Step 1 and does not recommend the use of ICS. The recommended dos-
ages of ICS for Steps 3 and 4 of the JPGL2002 are, however, smaller than those for Steps 2 and 3, respec-
tively, of the GINA. It should be clarified in future studies whether or not such a use of ICS can lead to earlier
and more frequent remission of asthma, hopefully resulting in the asthma being outgrown．
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INTRODUCTION
The Japanese Pediatric Guideline for the Treatment
and Management of Asthma was revised in Novem-
ber of 2002 by the 2002 Asthma Guideline Committee
of the Japanese Society of Pediatric Allergy and Clini-
cal Immunology. This revised guideline1 (JPGL2002)
shares the same concept with other asthma guide-
lines such as the Global Initiative for Asthma 20022
and 20033 (GINA) in the definition of asthma, the
airway pathology in and mechanisms of asthma, and
the diagnosis of asthma, but has several important
differences from other guidelines , especially in the
classification of the severity of and medications for
asthma. In this review, mainly these characteristic
features of the JPGL2002 will be discussed．
CLASSIFICATION OF ASTHMA SEVERITY IN
THE JPGL2002
The JPGL2002 provides criteria for classification of
asthma severity different from those of the GINA. As
shown in Figure 1, the JPGL2002 classifies asthma
severity into 4 steps according to the clinical features
before treatment : intermittent asthma (Step 1), mild
persistent asthma ( Step 2 ) , moderate persistent
asthma (Step 3) and severe persistent asthma (Step
4). This classification is similar to that of the GINA,
but the JPGL2002 divides Step 4 into Step 4―1 and
Step 4 ― 2, the latter including severe persistent
asthma which is resistant to appropriate medications
for Step 4―1．
However, the frequency of asthma symptoms and
other features of each step of the JPGL2002 are quite
different from those of the GINA ; those of each step
of the JPGL2002 are milder than those of the GINA.
Step 2 is included in Step 1 in the GINA ; Steps 3 and
4 are very similar to Steps 2 and 3, respectively, of the
GINA. The 2002 Japanese Pediatric Asthma Guide-
line Committee has adopted the JPGL2002 classifica-
tion because it seems more suitable for the classifica-
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GINAJPGL2002
STEP 1: Intermitent
Symptoms less than once a week
Brief exacerbations
Nocturnal symptoms not more than twice a month
Normal lung function between episodes
Seasonal cough and slight wheeze several times a year
Exacerbations with dyspnea with good response to β2-ago-
nist may occur 
STEP 2: Mild Persistent
Symptoms more than once a week but less than once a 
day
Exacerbations may afect activity and sleep
Nocturnal symptoms more than twice a month
Normal lung function between episodes
Cough and slight wheeze more than once a month but 
less than once a week
Brief exacerbation
STEP 3: Moderate Persistent
Symptoms daily
Exacerbations may afect activity and sleep
Nocturnal symptoms more than once a week
Daily use of inhaled short-acting β2-agonist
Slightly decreased lung function*
Cough and slight wheeze more than once a week but less 
than once a day
Exacerbations may afect activity and sleep
STEP 4: Severe Persistent
Symptoms daily
Frequent exacerbations
Frequent nocturnal asthma symptoms
Limitation of physical activities
Decreased lung function**
<STEP 4-1>
Cough and wheeze daily
Moderate to severe exacerbations afecting activity and 
sleep once to twice a week
<STEP 4-2>
Same as STEP 4-1 in spite of receiving appropriate medi-
cations against STEP 4-1
Fig. 1 Classification of asthma severity by clinical features before treatment in the JPGL2002 and GINA2002.
*60% < FEV1 < 80% predicted or 60% < PEF < 80% of personal best
**FEV1≦60% predicted or PEF≦60% of personal best
tion of asthma severity in childhood ; the clinical fea-
tures of each step of the GINA seem too severe for
the clinical features of childhood asthma. Asthmatic
children who have symptoms more than once a
month but less than once a week might be better con-
sidered as having mild persistent asthma (Step 2) ,
and asthmatic children with frequent symptoms such
as daily symptoms and nocturnal symptoms more
than once a week (Step 3 of the GINA) are rare in Ja-
pan and thus might be better considered as severe
persistent asthma (Step 4)．
The JPGL2002 also provides the classification of
asthma severity defined by daily medication regimen
and response to the treatmen(Fig. 2), which is similar
to that of the GINA.
MEDICATIONS
Another important characteristic of the JPGL2002 is
the medication protocol for each step of asthma, espe-
cially for long-term management. The JPGL2002 pro-
vides three different recommendations for long-term
asthma management according to the patients’ages :
for patients younger than 2 years, 2 to 5 years, and
older than 5 years(Figs. 3―5). A separate chapter for
infantile asthma is provided because it has many
characteristics different from those of older children
and needs special consideration. In each age group,
the recommended medications are defined according
to the levels of asthma severity.
INHALED GLUCOCORTICOSTEROID
Inhaled glucocorticosteroid (ICS) is defined as the
fundamental medicine for persistent asthma patients
in all three age groups, but the recommended dos-
ages for patients are different according to their ages.
ICS is recommended as the first-choice medicine for
patients older than 5 years with mild persistent or se-
verer asthma (Steps 2 to 4), whereas for patients at
the younger ages, ICS is only recommended as the
first-choice medicine for moderate and severe persis-
tent asthma (Steps 3 and 4). This is because a suit-
able formulation of ICS for young children, such as
the liquid type ICS, is not available in Japan and be-
cause Steps 2, 3, and 4 of the JPGL2002 are compara-
ble to Steps 1, 2 and 3, respectively, of the GINA, as
mentioned above．
Thus, in the JPGL2002, ICS is recommended for
less severe asthma patients older than 5 years ,
whereas the recommendation for younger patients is
very similar to the recommendation in the GINA. In




















































Fig. 2 Classification of asthma severity by daily medication regimen and response to treatment
ICS (300―400 μg/day)*
plus one or more of the 
folowing:
・Leukotriene modifier
・DSCG + β2 agonist** inha-
lation (twice a day)
・Sustained-release 
theophyline#
・Oral β2 agonist or 
sustained-release 
terbutaline (tape) before 
sleep**
ICS (―200 μg/day)*
plus one or more of the fol-
lowing if needed:
・Oral anti-alergic drug
・DSCG + β2 agonist** inha-
lation (twice a day)
・Sustained-release 
theophyline#
・Oral β2 agonist or 
sustained-release 
terbutaline (tape) before 
sleep**
Oral anti-alergic drug
plus one or more of the fol-
lowing if needed:
・DSCG + β2 agonist** inha-
lation (twice a day)
・Sustained-release 
theophyline#
ICS (―100 μg/day)* if 
needed
No daily controler medica-
tions necessary










Fig. 3　Recommended medications by level of severity: <2 y.o.
*CFC-BDP or equivalent
** Regular administration of β2 agonist should be ceased when asthma symptoms are controled.
#serum concentration 5―10 μg/m
##If asthma is not controled, more therapy including oral glucocorticosteroid administration should be considered as Step 4-2 
by specialists for pediatric alergy.
more than 60% of Japanese children with asthma, the
first symptoms are seen within the first 4 years of life,
suggesting that many asthma patients older than 5
years have already been suffering from asthma for
several years, and these patients categorized as hav-
ing persistent asthma, even mild persistent asthma as
defined by the JPGL 2002, need effective anti-
inflammatory medicines in order to prevent further
development of airway remodeling and to achieve
earlier outgrowing of the asthma．
It should be mentioned that the JPGL2002 recom-
mends smaller dosages of ICS for younger children.
Although the GINA reduced the recommendation
dosages of ICS in 2003 (GINA2003), the recommen-
dation dosages of the JPGL2002 are still smaller than
those of the GINA2003 for children at all ages. Other
medicines such as leukotriene modifiers and
sustained-release theophylline are recommended to
be added instead of using increased dosages of ICS
when the recommended dosage of ICS is insufficient
to control asthma symptoms. Because Steps 2 to 4 of
the JPGL2002 correspond more closely to milder
asthma patients than those of the GINA, and because
high dosages of ICS may show some systemic side ef-
fects, we think these smaller dosages may be better.
However, there is no definitive evidence to show that
the smaller dosages of ICS are sufficient to control
the allergic inflammation of asthma of younger chil-
dren, and therefore these recommended dosages of
ICS in the JPGL2002 should be justified by further
clinical study．
β2-AGONISTS
In the JPGL2002, β2-agonists are defined more clearly
as relievers but not as controllers. For longer use,
they should be used with ICS andor other control-
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ICS (300―600 μg/day)*
plus one or more of the 
folowing:
・Leukotriene modifier
・DSCG + β2 agonist** inha-
lation (twice a day)
・Sustained-release 
theophyline#
・Oral β2 agonist or 
sustained-release 
terbutaline (tape) before 
sleep**
ICS (200―300 μg/day)*
plus one or more of the fol-
lowing if needed:
・Oral anti-alergic drug
・DSCG + β2 agonist** inha-
lation (twice a day)
・Sustained-release 
theophyline#
・Oral β2 agonist or 
sustained-release 
terbutaline (tape) before 
sleep**
One or more of the folowing:
・DSCG + β2 agonist** inha-
lation (twice a day)
・Sustained-release 
theophyline#
ICS (―200 μg/day)* if 
needed
No daily controler medica-
tions necessary










Fig. 4 Recommended medications by level of severity: 2―5 y.o.
*CFC-BDP or equivalent
**Regular administration of β2 agonist should be ceased when asthma symptoms are controled.
#serum concentration 5―10 μg/ml
##If asthma is not controled, more therapy including oral glucocorticosteroid administration should be considered as Step 4-2 
by specialists for pediatric alergy.
ICS (400―800 μg/day)*























No daily controler medica-
tions necessary










Fig. 5 Recommended medications by level of severity: >5 y.o.
*CFC-BDP or equivalent
**When β2 agonist is inhaled in combination with DSCG, β2 agonist should be deleted when asthma symptoms are controled.
#serum concentration 5―10 μg/ml
##If asthma is not controled, more therapy including oral glucocorticosteroid administration should be considered as Step 4-2 
by specialists for pediatric alergy.
lers until asthma control is achieved , and after
asthma is controlled, β2-agonists should be ceased as
early as possible . However , there might be cases
when β2-agonists are necessary for considerably long
periods until asthma is controlled, especially in in-
fants and young children, because we have no formu-
lation of ICS suitable for the very young in Japan. In
such cases, the use of sustained-release terbutaline
(tape) before sleep might be valuable for preventing
nocturnal symptoms. Because we did not have suffi-
cient experience with long-acting β2-agonists such as
salmeterol for children in Japan in 2002, they would
need to be described and evaluated more clearly in
the next revision of the JPGL．
In the former JPGL (JPGL2000), regular inhalation
of disodium cromoglycate ( DSCG ) with small
amounts (0.05―0.1 ml) of salbutamol using a jet nebu-
lizer was recommended for patients with moderate
and severe persistent asthma. This medication has
been shown to be very effective for controlling
asthma symptoms of such patients4 and has become
very familiar in Japan. However, this medication may
be insufficient to control allergic inflammations and
remodeling of the lungs, at least in some cases. The
good effectiveness of regular inhalation of DSCG +
salbutamol for controlling asthma symptoms might
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lead to the misunderstanding that allergic inflamma-
tion of the lungs is also well controlled in such pa-
tients. Therefore, in the JPGL2002, regular inhalation
of DSCG + salbutamol is recommended until asthma
symptoms are controlled. When control is achieved,
inhalation of DSCG alone will be continued. If exacer-
bations then recur and asthma control cannot be
achieved without the addition of salbutamol , ICS
should be used instead of the extended regular use of
DSCG + salbutamol.
THEOPHYLLINE
Sustained-release theophylline is listed as a controller
in the JPGL2002 with a lower recommended serum
concentration (5―10μgml), which hopefully reduces
the possible side effects while keeping its anti-
inflammatory effect. To help achieve the safe and de-
sired effect of sustained-release theophylline, the ad-
ministration dosages are listed very precisely．
Intravenous administration of theophylline is also
listed in the JPGL2002 as a medication for acute exac-
erbation but with arguments against its effectiveness
and warning of possible undesirable effects due to in-
toxication.
TOPICS FOR THE NEXT REVISION OF THE
JPGL
The JPGL2002 first recommends ICS for asthmatic
children older than 5 years with symptoms more than
once a month but less than once a week (Step 2,
which is included in Step 1 in the GINA). The JPGL
2002 also recommends smaller dosages of ICS with
or without other controllers. It should be examined
whether or not the medication protocols of the JPGL
2002 can lead to earlier and more frequent remission
and outgrowing of asthma．
Another important point for revision might be the
application of intravenously administered theophyl-
line for acute exacerbation. The limited effectiveness
and relatively high risk of intoxication may raise argu-
ments against its being adopted for the asthma guide-
line used by all physicians.
Although the JPGL2002 does not mention much re-
garding long-acting β2-agonists such as salmeterol ,
the GINA recommends it as a controller for moderate
and severe persistent asthma when used in combina-
tion with ICS. In the next revision of the JPGL, the
same evaluation may be adopted although there are
only a few asthmatic children who need regular use
of a long-acting β2-agonist with ICS for a long period.
It does seem possible to evaluate long-acting β2-
agonists, just as one would the sustained-release ter-
butaline , as a supplemental medicine to ICS until
asthma symptoms are controlled．
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